leucovorin calcium / Generic mfg. 
Welcome,         Profile    Billing    Logout  
 424 Diseases   809 Trials   809 Trials   14393 News 


«12...107108109110111112113114115116117...235236»
  • ||||||||||  Vectibix (panitumumab) / Amgen, Takeda
    Journal:  Panitumumab Associated Acute Pancreatitis. (Pubmed Central) -  Jan 18, 2022   
    Although panitumumab related gastrointestinal side effects have been reported, there is no data on acute pancreatitis. Panitumumab was added to the chemotherapy regimen he received, and it was thought that panitumumab might be the etiological factor in the case who developed pancreatitis.
  • ||||||||||  irinotecan / Generic mfg.
    Journal, Circulating tumor DNA:  Exploring New Approaches for Locally Advanced Gastroesophageal Adenocarcinomas: TNT, irinotecan, and ctDNA. (Pubmed Central) -  Jan 15, 2022   
    FOLFIRI should be further studied in pancreatic cancers with HR-DDR defects. The authors of a recent pilot study incorporated novel concepts including total neoadjuvant therapy with induction triplet FOLFIRINOX then chemoradiotherapy before surgery, along with ctDNA minimal residual disease analyses demonstrating both feasibility of this approach as well as confirming prognostic value of ctDNA analysis before and after surgery.
  • ||||||||||  Avastin (bevacizumab) / Roche
    Clinical, Journal:  Personalizing First-Line Systemic Therapy in Metastatic Colorectal Cancer: Is There a Role for Initial Low-Intensity Therapy in 2021 and Beyond? A Perspective From Members of the Australasian Gastrointestinal Trials Group. (Pubmed Central) -  Jan 14, 2022   
    However, the relative benefit of a fluoropyrimidine doublet with oxaliplatin or irinotecan over single-agent fluoropyrimidine with or without a biologic is less certain; the available data demonstrate that single-agent fluoropyrimidine plus a biologic with planned sequencing of subsequent agents can produce similar overall survival outcomes with reduced toxicity...Established prognostic factors, including patient age, performance status, tumor sidedness, and biomarkers such as RAS/BRAF, are key in treatment selection; patients with left-sided RAS/BRAF wild-type disease or patients with low tumor bulk may be ideal for a less intensive regimen. Further studies are required to confirm the value of less-intensive regimens in the modern era, where the incorporation of biologic therapies has become routine and where non-chemotherapy options are emerging as viable options for molecularly defined patient subsets.
  • ||||||||||  Avastin (bevacizumab) / Roche, Erbitux (cetuximab) / Eli Lilly, EMD Serono
    Retrospective data, Journal:  Network Meta-analysis of First-Line Systemic Treatment for Patients With Metastatic Colorectal Cancer. (Pubmed Central) -  Jan 14, 2022   
    Trial registration Clinicaltrials.gov NCT04621370 (Registered 9th Nov 2020) EudraCT number 2019-001471-36 (Registered 6th Nov 2020). Our study supported the use of FOLFOXIRI plus bevacizumab as the best first-line regimen and potentially effective and safe strategy for the management of patients with mCRC.
  • ||||||||||  LY09004 (aflibercept biosimilar) / Luye Group, Ocumension Therap, Vectibix (panitumumab) / Amgen, Takeda
    Biomarker, Retrospective data, Journal:  An imaging signature to predict outcome in metastatic colorectal cancer using routine computed tomography scans. (Pubmed Central) -  Jan 14, 2022   
    It has been 16 mo since the start of the treatment, and the patient continues to demonstrate a complete durable response both serologically and radiologically. A signature combining three imaging features provides early prognostic information that can improve treatment decisions for individual patients and clinical trial analyses.
  • ||||||||||  5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg., docetaxel / Generic mfg.
    Clinical, Journal:  Perioperative FOLFOX in Patients With Locally Advanced Oesogastric Adenocarcinoma. (Pubmed Central) -  Jan 14, 2022   
    A signature combining three imaging features provides early prognostic information that can improve treatment decisions for individual patients and clinical trial analyses. Regarding its comparable efficacy and its favourable toxicity profile, perioperative FOLFOX is a reasonable alternative to FLOT for frail patients with resectable OGA.
  • ||||||||||  5-fluorouracil / Generic mfg., oxaliplatin / Generic mfg., leucovorin calcium / Generic mfg.
    Journal:  Deubiquitinase JOSD2 stabilizes YAP/TAZ to promote cholangiocarcinoma progression. (Pubmed Central) -  Jan 14, 2022   
    Further analysis has highlighted the positive correlation between JOSD2 and YAP abundance in CCA patient samples. Collectively, this study uncovers the regulatory effects of JOSD2 on YAP/TAZ protein stabilities and profiles its contribution in CCA malignant progression, which may provide a potential intervention target for YAP/TAZ-related CCA patients.
  • ||||||||||  EndoTAG-1 (paclitaxel liposomal) / Sinphar Pharma
    Trial completion, Trial completion date, Trial primary completion date, Metastases:  EndoTAG-1+GEM vs GEM in Patients With Locally Advanced/Metastatic Pancreatic Adenocarcinoma Failed on FOLFIRINOX (clinicaltrials.gov) -  Jan 14, 2022   
    P3,  N=218, Completed, 
    Collectively, this study uncovers the regulatory effects of JOSD2 on YAP/TAZ protein stabilities and profiles its contribution in CCA malignant progression, which may provide a potential intervention target for YAP/TAZ-related CCA patients. Active, not recruiting --> Completed | Trial completion date: Jan 2023 --> Oct 2021 | Trial primary completion date: Nov 2021 --> Jul 2021
  • ||||||||||  elraglusib (9-ING-41) / Actuate Therap
    Enrollment open, Metastases:  FOLFIRINOX + 9-Ing-41 + Losartan In Pancreatic Cancer (clinicaltrials.gov) -  Jan 13, 2022   
    P2,  N=70, Recruiting, 
    Trial completion date: Mar 2021 --> Jun 2022 | Trial primary completion date: Jan 2021 --> Jun 2022 Not yet recruiting --> Recruiting
  • ||||||||||  Avastin (bevacizumab) / Roche, Erbitux (cetuximab) / Eli Lilly, EMD Serono
    Journal:  Trends in Use and Perceptions About Triplet Chemotherapy Plus Bevacizumab for Metastatic Colorectal Cancer. (Pubmed Central) -  Jan 13, 2022   
    Triplet chemotherapy with fluorouracil, folinic acid, oxaliplatin, and irinotecan plus bevacizumab (FOLFOXIRI-B) is an effective first-line treatment option for patients with metastatic colorectal cancer (mCRC)...Of these 282 patients, 199 (71%) were treated with intensive first-line therapy other than FOLFOXIRI-B, of whom 184 (65%) were treated with oxaliplatin doublets with or without bevacizumab; 14 (5%) with irinotecan doublets with or without bevacizumab, panitumumab, or cetuximab; and 1 (0.4%) with irinotecan with bevacizumab...Considering that most medical oncologists discuss this treatment option, the prescription rate found in this study was below expectations. Awareness of guidelines and trial data seems to contribute to the discussion of available treatment options by medical oncologists, and the findings of this study suggest a need for repeated and continuing medical education.
  • ||||||||||  irinotecan / Generic mfg.
    Journal:  Plasma KRAS mutations predict the early recurrence after surgical resection of pancreatic cancer. (Pubmed Central) -  Jan 13, 2022   
    Although 12 patients (31%) given chemotherapy tested positive for plasma KRAS mutations, there was no demonstrable relation between plasma KRAS mutations and progression-free survival (PFS) or overall survival (OS) (p = .35 and p = .68, respectively). In patients with PDAC, detection of KRAS mutations in plasma proved independently predictive of early recurrence after surgical resection but did not correlate with PFS following chemotherapy.
  • ||||||||||  leucovorin calcium / Generic mfg., l-methylfolate / Generic mfg.
    Review, Journal:  The impact of glutathione metabolism in autism spectrum disorder. (Pubmed Central) -  Jan 12, 2022   
    Existing data support a protective role of the GSH system in ASD development. Future research should focus on the effects of GSH redox signaling in ASD and should explore new therapeutic approaches by targeting the GSH system.
  • ||||||||||  methotrexate IV / Generic mfg., methotrexate / Generic mfg.
    Clinical, Journal:  Effect of Polymorphisms of ABCB1 and MTHFR on Methotrexate-Related Toxicities in Adults With Hematological Malignancies. (Pubmed Central) -  Jan 11, 2022   
    In conclusion, we identified an important influence of the SNPs of ABCB1 and MTHFR on MTX-related hematopoietic toxicity in adults with hematological malignancies. To optimize high-dose (HD)-MTX therapy and reduce related hematopoietic toxicity, it is necessary to detect the SNPs of MTHFR and ABCB1 before initiating HD-MTX and deciding the optimal dose of MTX and duration of leucovorin rescue, according to genetic tests and disease type in adults with hematological malignancies.
  • ||||||||||  Zepsun (donafenib) / Suzhou Zelgen
    Enrollment open:  Neo-TACE: Neoadjuvant HAIC of TACE Plus Donafenib in BCLC B Stage HCC: a Multi-center Randomized Controlled Trial. (clinicaltrials.gov) -  Jan 11, 2022   
    P2/3,  N=156, Recruiting, 
    To optimize high-dose (HD)-MTX therapy and reduce related hematopoietic toxicity, it is necessary to detect the SNPs of MTHFR and ABCB1 before initiating HD-MTX and deciding the optimal dose of MTX and duration of leucovorin rescue, according to genetic tests and disease type in adults with hematological malignancies. Not yet recruiting --> Recruiting
  • ||||||||||  methotrexate IV / Generic mfg.
    Improving Knowledge Gaps Amongst Oncology Nurses to Minimize Chemotherapy Associated Toxicities: Standardized Education for High-Dose Methotrexate. (Salt Palace Convention Center Room 255 B) -  Jan 9, 2022 - Abstract #TCTASTCTCIBMTR2022TCT_ASTCT_CIBMTR_1390;    
    The errors centered on, proper parameter management prior to administration of drug, correct timing of serum methotrexate levels, and dosing and administration of leucovorin for cell rescue...Discussion & Implications A comprehensive education program and standardized approach is effective in reducing errors and improving outcomes for patients receiving HDMTX. Insight from multiple disciplines is key to identifying barriers and providing best practices to reduce errors and improve outcomes for patients